Spectrum Pharmaceuticals Announces Encouraging FOLOTYN, MARQIBO Clinical Data Presented at ASH

Spectrum Pharmaceuticals SPPI today announced encouraging clinical data from investigator-sponsored studies of MARQIBO® (vinCRIStine sulfate LIPOSOME injection) and FOLOTYN® (pralatrexate injection). “At the ASH meeting there were several presentations on our drugs and we are especially excited about two,” said Rajesh C. Shrotriya, M.D., Chairman, President and Chief Executive Officer of Spectrum Pharmaceuticals, Inc. “Data from Marqibo's Phase 2 study suggests the drug potentially could have utility in the treatment of Diffuse Large B-cell Lymphoma (DLBCL), in the front-line setting. DLBCL is a disease with a poor prognosis and See full press release